Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review

The Lancet

Volumn 389, Issue 10073, 2017, Pages 1035-1042

  Chow, Clara K ^a,b   Thakkar, Jay ^a,b   Bennett, Alex ^a   Hillis, Graham ^a,d   Burke, Michael ^c   Usherwood, Tim ^a   Vo, Kha ^a   Rogers, Kris ^a   Atkins, Emily ^a   Webster, Ruth ^a   Chou, Michael ^e   Dehbi, Hakim Moulay ^f   Salam, Abdul ^a   Patel, Anushka ^a,j   Neal, Bruce ^a,f,j   Peiris, David ^a   Krum, Henry ^g   Chalmers, John ^a   Nelson, Mark ^h   Reid, Christopher M ⁱ   Woodward, Mark ^a   Hilmer, Sarah ^a   Thom, Simon ^f   Rodgers, Anthony ^a   more..

^a UNIVERSITY OF SYDNEY   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

^c Kildare Road Medical Centre ^*  (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

^g MONASH UNIVERSITY   (Australia)

^h UNIVERSITY OF TASMANIA   (Australia)

ⁱ CURTIN UNIVERSITY   (Australia)

^j ROYAL PRINCE ALFRED HOSPITAL   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMLODIPINE; ASPARTATE AMINOTRANSFERASE; ATENOLOL; CREATININE; GLUCOSE; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; POTASSIUM; SODIUM; URATE; ANTIHYPERTENSIVE AGENT; BIPHENYL DERIVATIVE; TETRAZOLE DERIVATIVE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIHYPERTENSIVE THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD PRESSURE MONITORING; CHOLESTEROL BLOOD LEVEL; COMBINATION DRUG THERAPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DRY NOSE; FEMALE; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPERTENSION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; PATIENT COMPLIANCE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SIDE EFFECT; SODIUM BLOOD LEVEL; SWALLOW; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; URIC ACID BLOOD LEVEL; URINARY FREQUENCY; VERTIGO; BLOOD PRESSURE; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DRUG EFFECTS; LITERATURE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; ATENOLOL; BIPHENYL COMPOUNDS; BLOOD PRESSURE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MEDICATION ADHERENCE; MIDDLE AGED; REVIEW LITERATURE AS TOPIC; TETRAZOLES; TREATMENT OUTCOME;

EID: 85012907725     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)30260-X     Document Type: Article

References (31)

1. 1 Lim, SS, Vos, T, Flaxman, AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380 (2012), 2224–2260.
2. 2 Turnbull, F, for the Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 362 (2003), 1527–1535.
3. 3 Staessen, JA, Wang, JG, Thijs, L, Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 358 (2001), 1305–1315.
4. 4 Chow, CK, Teo, KK, Rangarajan, S, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 310 (2013), 959–968.
5. 5 Wald, DS, Law, M, Morris, JK, Bestwick, JP, Wald, NJ, Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 122 (2009), 290–300.
6. 6 Xie, X, Atkins, E, Lv, J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 387 (2016), 435–443.
7. 7 Wright, JT Jr, Williamson, JD, Whelton, PK, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373 (2015), 2103–2116.
8. 8 Law, MR, Wald, NJ, Morris, JK, Jordan, RE, Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ, 326, 2003, 1427.
9. 9 Brayfield, A, Martindale: the complete drug reference. http://www.pharmpress.com/product/MC_MART/martindale-the-complete-drug-reference (accessed Jan 18, 2017).
10. 10 MIMS. Monthly index of medical specialties. http://www.mims.com/resources/portal/common/document/mims/mimsau.htm (accessed Nov 17, 2016).
11. 11 National Heart Foundation of Australia. Guide to management of hypertension 2008: assessing and managing raised blood pressure in adults—updated. https://heartfoundation.org.au/images/uploads/publications/HypertensionGuidelines2008to2010Update.pdf, December, 2010 (accessed Jan 18, 2017).
12. 12 Kenward, MG, Roger, JH, The use of baseline covariates in crossover studies. Biostatistics 11 (2010), 1–17.
13. 13 Kenward, MG, Roger, JH, An improved approximation to the precision of fixed effects from restricted maximum likelihood. Comput Stat Data Anal 53 (2009), 2583–2595.
14. 14 Mahmud, A, Feely, J, Low-dose quadruple antihypertensive combination: more efficacious than individual agents: a preliminary report. Hypertension 49 (2007), 272–275.
15. 15 Wald, DS, Morris, JK, Wald, NJ, Randomized Polypill crossover trial in people aged 50 and over. PLoS One, 7, 2012, e41297.
16. 16 Wright, JT Jr, Whelton, PK, Reboussin, DM, A randomized trial of intensive versus standard blood-pressure control. N Engl J Med, 374, 2016, 2294.
17. 17 Drawz, PE, Pajewski, NM, Bates, JT, et al., for the SPRINT Study Research Group. Effect of intensive versus standard clinic-based hypertension management on ambulatory blood pressure: results from the SPRINT (Systolic Blood Pressure Intervention Trial) ambulatory blood pressure study. Hypertension 69 (2017), 42–50.
18. 18 Peterzan, MA, Hardy, R, Chaturvedi, N, Hughes, AD, Meta-analysis of dose-response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate. Hypertension 59 (2012), 1104–1109.
19. 19 Chang, SW, Gong, Y, McDonough, CW, et al. Melatonin pathway and atenolol-related glucose dysregulation: is there a correlation?. Clin Transl Sci 9 (2016), 114–122.
20. 20 Wright, JT Jr, Bakris, G, Greene, T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 288 (2002), 2421–2431.
21. 21 Hunsicker, LG, Adler, S, Caggiula, A, et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 51 (1997), 1908–1919.
22. 22 Lewis, EJ, Hunsicker, LG, Clarke, WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (2001), 851–860.
23. 23 Keane, WF, Brenner, BM, de Zeeuw, D, et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int 63 (2003), 1499–1507.
24. 24 Peralta, CA, McClure, LA, Scherzer, R, et al. Effect of intensive versus usual blood pressure control on kidney function among individuals with prior lacunar stroke: a post hoc analysis of the Secondary Prevention of Small Subcortical Strokes (SPS3) randomized trial. Circulation 133 (2016), 584–591.
25. 25 Cushman, WC, Evans, GW, Byington, RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362 (2010), 1575–1585.
26. 26 Law, MR, Morris, JK, Wald, NJ, Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ, 338, 2009, b1665.
27. 27 Sever, PS, Messerli, FH, Hypertension management 2011: optimal combination therapy. Eur Heart J 32 (2011), 2499–2506.
28. 28 Byrd, JB, Zeng, C, Tavel, HM, et al. Combination therapy as initial treatment for newly diagnosed hypertension. Am Heart J 162 (2011), 340–346.
29. 29 Feldman, RD, Zou, GY, Vandervoort, MK, Wong, CJ, Nelson, SA, Feagan, BG, A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension 53 (2009), 646–653.
30. 30 Salam, A, Webster, R, Singh, K, et al. TRIple pill vs Usual care Management for Patients with mild-to-moderate Hypertension (TRIUMPH): study protocol. Am Heart J 167 (2014), 127–132.
31. 31 Webster, R, Patel, A, Selak, V, et al. Effectiveness of fixed dose combination medication (“polypills”) compared with usual care in patients with cardiovascular disease or at high risk: a prospective, individual patient data meta-analysis of 3140 patients in six countries. Int J Cardiol 205 (2016), 147–156.